Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Rossari Biotech Earnings Call: Key Takeaways

Rossari Biotech reported highest-ever quarterly revenue of ₹684.9 cr and EBITDA of ₹77.3 cr in Q4 FY26. Performance driven by HPPC segment (77% of revenue) and capacity expansions.

Highlights
Revenue growth15.2% Y-o-Y for FY26.
MarginsEBITDA margin 11.9% for FY26; impacted by raw material inflation.
Demand visibilityHealthy double-digit growth in HPPC, TSC, and AHN segments.
Management confidenceHigh, citing strong R&D and balanced end-market exposure.

Growth

FY26 revenue grew 15.2% to ₹2,396.4 cr; PAT grew 9.4% to ₹149.2 cr. Q4 revenue surged 18.2% Y-o-Y.

Outlook

Unitop commissioned 15,000 MTPA ethoxylation capacity. FY27-28 focus on rephased capex, R&D at Koparkhairane, and international expansion.

Risks

Raw material price volatility and lag in passing on cost inflation impacted quarterly margins (11.3% vs 12.0% Y-o-Y).

Source

Earnings Call filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.

Read the document ↗

Rossari Biotech Ltd: key numbers

Share price
₹444.20
Market cap
₹2,461 Cr
Revenue (annual)
₹2,396 Cr
Net profit (annual)
₹149.2 Cr
P/E (TTM)
16.3×Sector 37.5×
Promoter holding
68.14%-0.01% QoQ
FII holding
2.03%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Rossari Biotech Ltd

All →